4.39
+0.26(+6.30%)
Currency In USD
| Previous Close | 4.13 |
| Open | 4.14 |
| Day High | 4.45 |
| Day Low | 3.95 |
| 52-Week High | 10.8 |
| 52-Week Low | 1.31 |
| Volume | 51,554 |
| Average Volume | 804,731 |
| Market Cap | 93.24M |
| PE | -0.4 |
| EPS | -10.85 |
| Moving Average 50 Days | 3.24 |
| Moving Average 200 Days | 2.82 |
| Change | 0.26 |
If you invested $1000 in CalAmp Corp. (CAMP) 10 years ago, it would be worth $10.27 as of November 13, 2025 at a share price of $4.39. Whereas If you bought $1000 worth of CalAmp Corp. (CAMP) shares 5 years ago, it would be worth $22.56 as of November 13, 2025 at a share price of $4.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire Inc.
Nov 06, 2025 9:05 PM GMT
Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders Initiated Good Laboratory Practice (GLP) toxicology studies for CMP-002 in support of a planned clin
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
GlobeNewswire Inc.
Oct 01, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
GlobeNewswire Inc.
Sep 10, 2025 11:00 AM GMT
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of proceeds to fund the Phase 1/2 clinic